Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

BACKGROUND: Hepatic impairment can impact apixaban pharmacokinetics and pharmacodynamics by decreasing cytochrome P450-mediated metabolism and factor X production. OBJECTIVE: This study evaluated the effect of mild or moderate (Child–Pugh A and B) hepatic impairment on apixaban pharmacokinetics, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Charles E., Ly, Van, Garonzik, Samira M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602549/
https://www.ncbi.nlm.nih.gov/pubmed/34363188
http://dx.doi.org/10.1007/s40268-021-00359-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602549/
https://www.ncbi.nlm.nih.gov/pubmed/34363188
http://dx.doi.org/10.1007/s40268-021-00359-y

Ejemplares similares